RNS Number: 3440 Z Redx Pharma plc 09 January 2020 FORM 8. PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER. Rules 8.1 and 8.2 of the Takeover Code.
RNS Number: 2133 Z Redx Pharma plc 09 January 2020. THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN..
RNS Number: 7309 Y Redx Pharma plc 03 January 2020. The General Meeting will be held at the offices of Covington& Burling LLP, 265 Strand, London, WC2R 1 BH at 11.00 am on 21 January 2020.. Redx is a UK based biotechnology company whose shares are traded on AIM.
RNS Number: 3269 Y Redx Pharma plc 31 December 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
RNS Number: 8090 T Redx Pharma plc 19 November 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN..
RNS Number: 7019 S Redx Pharma plc 07 November 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2003 N Redx Pharma plc 23 September 2019 REDX PHARMA PLC. Poster presentation at ERS Congress highlights RXC006 as a novel and promising drug candidate for the treatment of idiopathic pulmonary fibrosis. Alderley Park, 23 September 2019 Redx Pharma, the drug discovery and development company focused on cancer and fibrosis, announces that the...
Redx Pharma Plc (REDX.L) Announced that it has successfully completed dosing of the first cohort of patients in its ongoing phase 1/2 study with RXC004. Following a review of the data from this cohort, the Safety Review Committee has recommended that the dose can now be escalated. Consequently, recruitment of the second patient cohort, who will be administered the drug at a higher pre-specified dose of RXC004, has begun as per the trial protocol.
RNS Number: 4081 J Redx Pharma plc 19 August 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Redx Pharma Plc (REDX.L) Announced that it has signed a definitive agreement with Jazz Pharmaceuticals plc (Jazz) under which Jazz has acquired the company’s pan-RAF inhibitor programme for the potential treatment of RAF and RAS mutant tumours. Jazz will be responsible for all future development, regulatory, manufacturing and commercialisation activities. Under the terms of the agreement, Jazz will pay an upfront payment of $3.5 million in cash for all rights, title and interest relating to the company’s proprietary pan-RAF inhibitor programme, including all related patents. The company is eligible to receive up to $203 million in development, regulatory and commercial milestone payments from Jazz, with the next milestones being initiation of IND enabling studies, followed by a further milestone at IND submission to the FDA. It is also eligible for incremental tiered royalties in mid-single digit percentage, based on any future net sales.
Redx Pharma (REDX.L) 14.5p £7.9m Redx Pharma announced that it has signed a definitive agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ; "Jazz") under which Jazz has acquired Redx's pan-RAF inhibitor programme for the potential treatment of RAF and RAS mutant tumours. Jazz will be responsible for all future development, regulatory, manufacturing and commercialisation activities. Under the terms of the agreement, Jazz will pay Redx an upfront payment of $3.5 million in cash for all rights, title and interest relating to Redx's proprietary pan-RAF inhibitor programme, including all related patents. Redx is eligible to receive up to $203m in development, regulatory and commercial milestone payments from Jazz, with the next milestones being initiation of IND enabling studies, followed by a further milestone at IND submission to the FDA. Redx is also eligible for incremental tiered royalties in mid-single digit percentage, based on any future net sales. As part of a separate collaboration agreement, signed in parallel, Jazz will pay Redx to perform research and preclinical development services with the goal of completing IND-enabling studies.
Redx to receive $3.5 million upfront, up to $203 million in milestone payments and royalty payments. Under the terms of the agreement, Jazz will pay Redx an upfront payment of $3.5 million in cash for all rights, title and interest relating to Redx's proprietary pan-RAF inhibitor programme, including all related patents. Redx is eligible to receive up to $203...
REDX Pharma (REDX.L) 5.25p £6.64m FY mar 19 results from the drug discovery and development Group. “In our 2018 annual report the Board and Management set out our strategy, focused on moving RXC004, our porcupine inhibitor programme for Wnt driven cancer, back into the clinic. We also set out our plan to move RXC006, a porcupine inhibitor targeted at idiopathic pulmonary fibrosis, into preclinical development as well as selecting a development candidate for our ROCK2 programme for fibrosis. Throughout the first six months of the year we have made progress against these aims, most notably reinitiating our phase 1 clinical trial of RXC004 .” “Short-term loan agreement of up to £2.5m from Moulton Goodies Ltd (MGL), the Company's largest shareholder, which extends our cash runway into the fourth quarter of 2019.”
Redx Pharma Plc (REDX.L) Announced, in its interim results for the six months ended 31 March 2019, that its loss from operations stood at £4.05 million, compared to £4.96 million in the preceding year. The company’s diluted loss per share was 1.8p, compared to 3.6p. Separately, the company announced that it has signed an agreement with Moulton Goodies Ltd. for a fixed rate secured loan note facility of up to £2.5 million.
RNS Number: 6020 B Redx Pharma plc 10 June 2019 REDX PHARMA PLC. Today, we announced that we have signed a short-term loan agreement of up to £2.5 million from Moulton Goodies Ltd, the Company's largest shareholder, which extends our cash runway into the fourth quarter of 2019. We continue to be in active discussions with shareholders and third-party healthcare...
RNS Number: 6015 B Redx Pharma plc 10 June 2019 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION. Further to the announcement released on 3 May 2019, the Board is pleased to announce that the Company has signed an agreement with Moulton Goodies Ltd....
Redx Pharma Plc
REDX.L
Redx Pharma Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    126.48M

Company Profile

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.

Classification

Market Indices-

Locations

HQ
Alderley Park
Mereside
Block 33
Macclesfield
SK10 4TG
Watchlist